scholarly journals Real‐World Data Related to the Topics of 6th Edition of Gastric Cancer Treatment Guidelines

2021 ◽  
Author(s):  
Hideaki Shimada
Keyword(s):  
Gastric Cancer ◽  
Cancer Treatment ◽  
Real World ◽  
Treatment Guidelines ◽  
Real World Data ◽  
World Data ◽  
Gastric Cancer Treatment

scholarly journals Trastuzumab-based palliative chemotherapy for HER2-positive gastric cancer: a single-center real-world data

BMC Cancer ◽  
2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Tae-Hwan Kim ◽  
Hun Do Cho ◽  
Yong Won Choi ◽  
Hyun Woo Lee ◽  
Seok Yun Kang ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Real World ◽  
Group Performance ◽  
Eastern Cooperative Oncology Group ◽  
Conversion Surgery ◽  
Single Center ◽  
Her2 Positive ◽  
Real World Data ◽  
World Data ◽  
The Real

Abstract Background Since the results of the ToGA trial were published, trastuzumab-based chemotherapy has been used as the standard first-line treatment for HER2-positive recurrent or primary metastatic gastric cancer (RPMGC). However, the real-world data has been rarely reported. Therefore, we investigated the outcomes of trastuzumab-based chemotherapy in a single center. Methods This study analyzed the real-world data of 47 patients with HER2-positive RPMGC treated with trastuzumab-based chemotherapy in a single institution. Results With the median follow-up duration of 18.8 months in survivors, the median overall survival (OS) and progression-free survival were 12.8 and 6.9 months, respectively, and the overall response rate was 64%. Eastern Cooperative Oncology Group performance status 2 and massive amount of ascites were independent poor prognostic factors for OS, while surgical resection before or after chemotherapy was associated with favorable OS, in multivariate analysis. In addition, 5 patients who underwent conversion surgery after chemotherapy demonstrated an encouraging median OS of 30.8 months, all with R0 resection. Conclusions Trastuzumab-based chemotherapy in patients with HER2-positive RPMGC in the real world demonstrated outcomes almost comparable to those of the ToGA trial. Moreover, conversion surgery can be actively considered in fit patients with a favorable response after trastuzumab-based chemotherapy.

scholarly journals Evaluation of the Japanese Gastric Cancer Association?s Gastric Cancer Treatment Guidelines for Popular Use

2004 ◽  
Vol 7 (1) ◽  
pp. 41-45
Author(s):  
Takashi Ichikura ◽  
Toshiya Ogawa ◽  
Takashi Majima ◽  
Susumu Saigusa ◽  
Yoshihisa Yaguchi ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Cancer Treatment ◽  
Treatment Guidelines ◽  
Japanese Gastric Cancer Association ◽  
Gastric Cancer Treatment

Surgery for metastases for esophageal-gastric cancer in the real world: Data from the AGAMENON national registry

2018 ◽  
Vol 44 (8) ◽  
pp. 1191-1198 ◽  
Author(s):  
Alberto Carmona-Bayonas ◽  
Paula Jiménez-Fonseca ◽  
Isabel Echavarria ◽  
Manuel Sánchez Cánovas ◽  
Gema Aguado ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Real World ◽  
National Registry ◽  
Real World Data ◽  
World Data ◽  
The Real

Tumor response and growth rate of nivolumab treatment in advanced gastric cancer: Real-world data from a large observational/translational study, JACCRO GC-08 (deliver trial).

2020 ◽  
Vol 38 (15_suppl) ◽  
pp. 4527-4527
Author(s):  
Ryohei Kawabata ◽  
Yasuhiro Sakamoto ◽  
Eisuke Inoue ◽  
Atsushi Ishiguro ◽  
Yusuke Akamaru ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Clinical Trial ◽  
Growth Rate ◽  
Tumor Growth ◽  
Real World ◽  
Fold Increase ◽  
Real World Data ◽  
World Data ◽  
Translational Study ◽  
Before And After

4527 Background: Nivolumab (Nivo) demonstrated survival benefit in previously treated gastric cancer (GC) patients (pts), with a response rate (RR) of 11% and a disease control rate (DCR) of 40% (Kang YK, et al. Lancet 2017). There are few real-world data of Nivo and its predictive markers are needed in GC. It has been demonstrated that some tumors grow rapidly after Nivo treatment, but the proportion is uncertain. Methods: DELIVER trial was a prospective, multicenter, observational/translational study which assessed pts with advanced GC treated with Nivo alone and ECOG Performance Status (PS) 0-2 (UMIN000030850). The aims were to evaluate the efficacy and safety of Nivo in real world, and to discover novel host-related immune-biomarkers (gut microbiome, genetic polymorphism, gene expression, and metabolome) using fecal and blood samples which were collected before and after Nivo treatment. The RR, DCR, progression-free survival, overall survival, and tumor growth rate (TGR) were estimated as the efficacy. The response was evaluated by first imaging based on RECIST version 1.1. The TGR was calculated as a percentage increase in tumor volume during 1 month (Champiat et al. Clin Cancer Res 2017). Results: A total of 501 pts was enrolled in this study from Mar 2018 to Aug 2019, and 487 pts were evaluable for analysis (median age 70-y, 71% male, ECOG PS0/1/2 42%/44%/14%, tub/por/sig 45%/41%/5%, 21% HER2-pos, 42% pts with ascites). The DCR was 39.2% (95%CI 34.9-43.7) in evaluable pts. In 282 pts with measurable lesions, the RR was 6.7% (95%CI 4.1-10.3) and DCR was 36.5%. Sub-analysis by patient background indicated that DCR was 41% for PS0, 42% for PS1, and 24% for PS2. In addition, the DCR was lower in pts with ascites compared to those without ascites (28.6% vs. 47.0%, p= 0.005). The TGR decreased after introduction of Nivo in 124 (56.6%) of 219 evaluable pts for TGR; however, 20.5% pts were identified as experiencing hyper-progressive disease (HPD) which was defined as a ≥2-fold increase of the TGR before and after Nivo. When defining HPD as a ≥2-fold increase of tumor growth kinetics ratio and 50% increase of tumor burden, 9.6% pts experienced it. Conclusions: The real-word data of the large observational trial showed a comparable DCR to that of clinical trial in advanced GC treated with Nivo. This trial revealed the tumor behavior and some pts who experienced rapid tumor growth after Nivo treatment in clinical practice; biomarkers for HPD and the definition should be established. Clinical trial information: UMIN000030850 .

scholarly journals Real-World Data Analysis of Cancer Treatment Cost Drivers By Type and Place of Service

2017 ◽  
Vol 20 (9) ◽  
pp. A430
Author(s):  
J Scott ◽  
C Alcorn ◽  
D Garofalo ◽  
J Montgomery
Keyword(s):  
Data Analysis ◽  
Cancer Treatment ◽  
Real World ◽  
Treatment Cost ◽  
Real World Data ◽  
World Data ◽  
Cost Drivers
Sign in / Sign up

Export Citation Format

Share Document